VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Wróbel, Tomasz ^a   Mazur, Grzegorz ^a   Dzietczenia, Justyna ^a   Gȩbura, Katarzyna ^b   Kuliczkowski, Kazimierz ^a   Bogunia Kubik, Katarzyna ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; GENETIC MARKER;

ADULT; ALLELE; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOZYGOSITY; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ADOLESCENT; AGED; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MORTALITY; POLAND; PREVALENCE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT; EPIDEMIOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84884262529     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/159813     Document Type: Article

References (28)

1. Ribatti D., Vacca A., Nico B., Fanelli M., Roncali L., Dammacco F., Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. European Journal of Haematology 1996 56 1-2 45 53 2-s2.0-0029995264
2. Ho C. L., Sheu L. F., Li C. Y., Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Applied Immunohistochemistry and Molecular Morphology 2002 10 4 316 321 2-s2.0-0036900804 10.1097/00022744- 200212000-00005
3. Salven P., Orpana A., Teerenhovi L., Joensuu H., Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000 96 12 3712 3718 2-s2.0-0034548821
4. Vincenti V., Cassano C., Rocchi M., Persico M. G., Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996 93 8 1493 1495 2-s2.0-0029868465
5. Brogan I. J., Khan N., Isaac K., Hutchinson J. A., Pravica V., Hutchinson I. V., Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Human Immunology 1999 60 12 1245 1249 2-s2.0-0033400238 10.1016/S0198-8859(99)00132-9
6. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., Inoue I., Katayama S., A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002 51 5 1635 1639 2-s2.0-0036316846
7. Stevens A., Soden J., Brenchley P. E., Ralph S., Ray D. W., Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Research 2003 63 4 812 816 2-s2.0-0037442985
8. Ray D., Mishra M., Ralph S., Read I., Davies R., Brenchley P., Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004 53 3 861 864 2-s2.0-1442349965 10.2337/diabetes.53.3.861
9. Watson C. J., Webb N. J. A., Bottomley M. J., Brenchley P. E. C., Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000 12 8 1232 1235 2-s2.0-0033865580 10.1006/cyto.2000.0692
10. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., Pilger E., A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. Journal of Vascular Research 2000 37 6 443 448 2-s2.0-0034509524 10.1159/000054076
11. Lafage-Pochitaloff M., Galland F., Simonetti J., Prats H., Mattei M. G., Birnbaum D., The human basic fibroblast growth factor gene is located on the long arm of chromosome 4 at bands q26-q27. Oncogene Research 1990 5 3 241 244 2-s2.0-0025261378
12. Beránek M., Tschöplová S., Kanková K., Kuhrová V., Vácha J., Genetic variation in the promoter region of the basic fibroblast growth factor gene. Human Immunology 2003 64 3 374 377
13. Papazoglou D., Galazios G., Papatheodorou K., Liberis V., Papanas N., Maltezos E., Maroulis G. B., Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss. Fertility and Sterility 2005 83 4 959 963 2-s2.0-17044362604 10.1016/j.fertnstert.2004.12.017
14. Galimberti S., Nagy B., Palumbo G. A., Ciancia E., Buda G., Orciuolo E., Melosi A., Lambelet P., Ronca F., Petrini M., Vascular endothelial growth factor polymorphisms in mantle cell lymphoma. Acta Haematologica 2010 123 2 91 95 2-s2.0-72149134653 10.1159/000267826
15. Kariž S., Grabar D., Krkovič M., Osredkar J., Petrovič D., Polymorphisms in the promoter region of the basic fibroblast growth factor gene are not associated with myocardial infarction in a slovene population with type 2 diabetes. Journal of International Medical Research 2009 37 5 1596 1603 2-s2.0-70449674884
16. Petrovič M. G., Krkovič M., Osredkar J., Hawlina M., Petrovič D., Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes. Clinical and Experimental Ophthalmology 2008 36 2 168 172 2-s2.0-41249088219 10.1111/j.1442-9071.2007.01647.x
17. Hazar B., Paydas S., Zorludemir S., Sahin B., Tuncer I., Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leukemia and Lymphoma 2003 44 12 2089 2093 2-s2.0-0242550768 10.1080/1042819031000123519
18. Paydas S., Seydaoglu G., Ergin M., Erdogan S., Yavuz S., The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leukemia and Lymphoma 2009 50 3 366 373 2-s2.0-67650892411 10.1080/10428190802706665
19. Klein S., Roghani M., Rifkin D. B., Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. EXS 1997 79 159 192 2-s2.0-0030641614
20. Giles F. J., Vose J. M., Do K. A., Johnson M. M., Manshouri T., Bociek G., Bierman P. J., O'Brien S. M., Kantarjian H. M., Armitage J. O., Albitar M., Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leukemia Research 2004 28 6 595 604 2-s2.0-11144354408 10.1016/j.leukres.2003.11.002
21. Wróbel T., Mazur G., Usnarska-Zubkiewicz L., Kuliczkowski K., Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients. Polskie Archiwum Medycyny Wewnetrznej 2004 112 2 919 923 2-s2.0-4944256843
22. Jørgensen J. M., Sørensen F. B., Bendix K., Nielsen J. L., Funder A., Karkkainen M. J., Tainola T., Sørensen A. B., Pedersen F. S., D'Amore F., Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leukemia and Lymphoma 2009 50 10 1647 1660 2-s2.0-70350747488 10.1080/10428190903156729
23. Diao L. P., Yu X. M., Gao Y. H., Li Y., Liu H. S., Liu L. H., Zhou R. M., Wang N., Wu L. L., Wang S. J., Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma. Journal of Cancer Research and Clinical Oncology 2009 135 11 1473 1481 2-s2.0-70349565954 10.1007/s00432-009-0650-0
24. Kim M. K., Suh C., Chi H. S., Cho H. S., Bae Y. K., Lee K. H., Lee G. W., Kim I. S., Eom H. S., Kong S. Y., Bae S. H., Ryoo H. M., Shin I. H., Mun Y. C., Chung H., Hyun M. S., VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Science 2012 103 3 497 503 2-s2.0-84859726033 10.1111/j.1349-7006.2011.02168.x
25. Wróbel T., Poreba M., Mazur G., Poreba R., Pyszel A., Beck B., Steinmetz-Beck A., Andrzejak R., Kuliczkowski K., Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma. Neoplasma 2006 53 3 253 258 2-s2.0-33744905366
26. Stopeck A. T., Unger J. M., Rimsza L. M., LeBlanc M., Farnsworth B., Iannone M., Glenn M. J., LeBlanc M., Farnsworth B., Iannone M., Glenn M. J., A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 2012 120 6 1210 1217 10.1182/blood-2012-04-423079
27. Mazur G., Bogunia-Kubik K., Wrobel T., Kuliczkowski K., Lange A., TGF- β 1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine 2006 33 3 145 149 2-s2.0-33644897587 10.1016/j.cyto.2005.12.010
28. Bogunia-Kubik K., Mazur G., Wróbel T., Kuliczkowski K., Lange A., Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008 71 2 146 150 2-s2.0-38049161446 10.1111/j.1399-0039.2007.00984.x